Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 ...

Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.